Doximity price target lowered to $58 from $67 at Canaccord

Canaccord lowered the firm’s price target on Doximity (DOCS) to $58 from $67 and keeps a Hold rating on the shares. The firm said they posted a strong beat and the previously implied 2H FY’26 guidance was essentially maintained which seemed to drive the shares lower. Canaccord said the conservative stance comes from potential DTC advertising and drug pricing changes that have the possibility to drive Pharma management to alter budgets in remaining months of calendar 2025 and plans for calendar 2026.